Replies to post #1902 on Fresenius Kabi Pharmaceuticals (APCVZ)

[sigma_x]

So to Ka-Ching: Sorry, I thought you were talking about me in your post. (Still think your ID merits derision, though. But, anyway - all the best!)

As for the rest of you - you have to ask yourself, "will U.S. sales for these two drugs help them achieve $531 mln in EBITDA in the next 3 qtrs.?"

I don't know.

The ultimate goal is 1.267 Bln spread out over 3 years. They're $531 mln away from making that goal. It took them 9 qtrs. to make $736,000,000. So, bearing in mind that they can count the U.S. sales of these two pretty big cancer drugs towards their EBITDA, plus you have this (which went virtually unnoticed earlier this month...

http://www.avma.org/onlnews/javma/may10/...

So they've been making on average about $81 mln a qtr for the last 9 qtrs. Can they now expect to report adjusted EBITDA of $177 mln a qtr for the next 3 qtrs.?

THAT is the 980 million dollar question.